Clinical trials: Steatosis
NASH With Fibrosis
A Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With NASH F3
This is a randomized, open-label, parallel-dosing, multi-center study to evaluate the safety and efficacy of rencofilstat as evidenced by assessing changes in the HepQuant Shunt Disease Severity Index Score (DSI), safety labs…
- Trial name
- ALTITUDE (NCT05461105)
- Testing
- rencofilstat, 75 mg, rencofilstat, 150mg, rencofilstat, 225 mg
- Where
- 20 sites in United States
- Volunteers
- 60 people
- Sponsor
- Hepion Pharmaceuticals, Inc.
Fibrosis of Liver
Establishment of NAFLD Cohort and Development of Fibrosis Markers
This study is designed for establishment of non-alcoholic fatty liver disease patients cohort to development of markers to predict histologic progression of liver fibrosis.
- Trial name
- NAFLD (NCT02206841)
- Testing
- Liver biopsy, ARFI, SWE
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Seoul National University Boramae Hospital
Steatohepatitis, Nonalcoholic, Osteo Arthritis
DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine
This is a Phase 1, open-label, 2-part, fixed-sequence, single-center, two-period, drug-drug interaction trial in healthy adult participants to determine if ECC0509 administration at steady state affects the pharmacokinetics (PK)…
- Trial name
- NCT07873229
- Testing
- ECC0509, Metformin, Caffeine
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eccogene
Cardiovascular Diseases
Molecular Investigation of Genetic Factors in CArDiovascular Diseases Using an BIOresource of Healthy Volunteers
The risk of cardiovascular disease is determined by the complex interplay between an individual's genetic make-up, lifestyle, and the environment.
- Trial name
- CADBIO (NCT03038750)
- Testing
- Eligibility and lifestyle restrictions check., Medical history, demographic and lifestyle factors, Anthropometric measurements: height, weight, and body fat
- Where
- United Kingdom
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Obesity, Diabetes
Epigenetic Mechanisms and Severe Obesity (Biological Tissue Collection)
The purpose of this study was to evaluate the role of vitamin status and epigenetic mechanisms on severe obesity related-complications.
- Conditions
- Obesity, Diabetes, Metabolic Diseases, Non-alcoholic Fatty Liver Disease
- Trial name
- OBESEPI (NCT02663388)
- Testing
- gastric bypass, sleeve, gastric banding
- Where
- France
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- University of Lorraine
Non-alcoholic Fatty Liver Disease
Effect of Ginger Supplement on Non-alcoholic Fatty Liver
The hypothesis of this study was that ginger supplement consumption can be introduced as a new therapeutic strategy for non-alcoholic fatty liver disease through the improved body antioxidant activity, reduced levels of…
- Trial name
- NCT02535195
- Testing
- Ginger supplement
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Dr Azita Hekmatdoost
Non-alcoholic Steatohepatitis
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
This study will evaluate the efficacy, safety, and pharmacokinetics of BFKB8488A compared to placebo in participants with non-alcoholic steatohepatitis (NASH).
- Trial name
- BANFF (NCT04171765)
- Testing
- BFKB8488A
- Where
- 53 sites in United States, Belgium and 3 more
- Volunteers
- 46 people
- Sponsor
- Genentech, Inc.
Nonalcoholic Steatohepatitis
Digoxin for Patients With Non-alcoholic Steatohepatitis (NASH)
The purpose of this study is to assess if digoxin is safe and efficacious in treating patients with non-alcoholic steatohepatitis (NASH) within the approved target range of 0.7 to 1 ng/ml.
- Trial name
- NCT04216693
- Testing
- Digoxin tablet
- Where
- China
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2
Multi-Parametric MRI Assessment of the Liver in Diabetic Volunteers (Partners Registry)
To build a registry of diabetic volunteers by inviting them to get a LiverMultiScan and collecting their contact information to seek interest in participating in future research studies.
- Trial name
- NCT04336800
- Testing
- LiverMultiscan
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Perspectum
Nonalcoholic Fatty Liver Disease
Gastric Bypass Stent Small-Sample-Size Study For Nonalcoholic Fatty Liver Disease
Evaluate the preliminary effectiveness and safety of the Gastric Bypass Stent System in treating nonalcoholic fatty liver disease.
- Trial name
- NCT05495139
- Testing
- Gastric Bypass Stent System in Treatment of Patients with Nonalcoholic Fatty Liver Disease
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hangzhou Tangji Medical Technology Co., Ltd.
Nonalcoholic Steatohepatitis
Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis
The purpose of the study is to see if the drug colesevelam is a potential treatment for Nonalcoholic Steatohepatitis(NASH).
- Trial name
- NCT01066364
- Testing
- Colesevelam Hcl
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- University of California, San Diego
Metabolic-associated Fatty Liver Disease
Efficacy and Safety of Rifaximin in Treating MAFLD
Study Objective: to evaluate the efficacy and safety of rifaximin in the treatment of metabolic-associated fatty liver disease (MAFLD), and investigate the underlying mechanisms by which rifaximin influence MAFLD progression.
- Trial name
- NCT07185932
- Testing
- Rifaximin (Xifaxan)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Changzheng Hospital
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
GLUT-F Improves MASLD Liver Function
This randomized, double-blind, placebo-controlled, two-period crossover study evaluated the effects of GLUT-F, a nutraceutical formulation containing silibin-enriched silymarin, glutathione, and vitamin E delivered with…
- Trial name
- GLUT-F (NCT07724067)
- Testing
- GLUTatios FOrte
- Where
- Italy
- Volunteers
- 42 people
- Sponsor
- University of Bari
Non-alcoholic Steatohepatitis, Fibrosis
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
This is a multicenter, double-blind, randomized, placebo-controlled trial involving subjects with a diagnosis of "definite NASH" with fibrosis (excluding cirrhosis) as determined by the central histopathologist.
- Conditions
- Non-alcoholic Steatohepatitis, Fibrosis, Liver Diseases
- Trial name
- ENCORE-NF (NCT02686762)
- Testing
- Emricasan (5 mg), Emricasan (50 mg)
- Where
- 103 sites in United States, Germany and 1 more
- Volunteers
- 318 people
- Sponsor
- Conatus Pharmaceuticals Inc.
Insulin Resistance, Prediabetic State
Dexamethasone/Pancreatic Clamp P&F
This is a single-center, prospective, randomized, controlled (crossover) clinical study designed to investigate the specific dose-response impact of insulin infusion rate (IIR) on blood glucose levels during a pancreatic clamp…
- Conditions
- Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
- Trial name
- NCT06126354
- Testing
- Insulin human, Octreotide Acetate, Glucagon
- Where
- United States
- Sponsor
- Columbia University
Hepatic Steatosis
A Pilot, Dose Escalating Study on VLX103 in Moderate Alcoholic Steatohepatitis
The study drug (VLX103) is being developed for the treatment of Alcoholic Steatohepatitis and other liver diseases. Alcoholic Steatohepatitis is an inflammatory (associated with irritation, swelling and cell damage) disease that…
- Trial name
- NCT03201159
- Testing
- VLX103
- Where
- United States
- Sponsor
- Gyongyi Szabo
Non-Alcoholic Fatty Liver Disease
Characterization and Technical Evaluation of cT1 for NASH (CATE-NASH)
The primary objective of this study is to evaluate to provide evidence to establish tightly defined cut-offs to identify patients for NASH clinical trial inclusion using cT1 and/or PDFF.
- Trial name
- NCT04341246
- Testing
- LiverMultiscan
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Perspectum
Obesity, Morbid, NASH - Nonalcoholic Steatohepatitis
Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
This study is being done to better understand the relationship between inflammation in adipose tissue (AT), abnormal deposition of fat around the liver and how this affects its appearance and function and ultimately insulin…
- Conditions
- Obesity, Morbid, NASH - Nonalcoholic Steatohepatitis, Chronic Inflammation
- Trial name
- NCT04232566
- Testing
- Bariatric surgery
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Metabolic Associated Fatty Liver Disease
Lifestyle Modification for MAFLD Based on TTM
Lifestyle changes aiming at weight loss remain the cornerstone of MAFLD treatment.Evaluating the motivational stage of patients' change and providing targeted lifestyle guidance may significantly improve the efficiency of weight…
- Trial name
- NCT04871880
- Testing
- Dietitian led life style modification intervention, Conventional care (control)
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Fatty Liver Disease
Assessment of FibbroScan in Diagnosing MASLD Among the Chinese Population With Obesity
The non-invasive evaluation of liver steatosis and fibrosis with FibroScan is a routinely procedure in clinical practice for people with obesity.
- Trial name
- MASLD (NCT06720766)
- Testing
- FibbroScan and biopsy
- Where
- China
- Volunteers
- 565 people
- Sponsor
- The Third People's Hospital of Chengdu
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.